Drawing for IBS.SMART

USPTO serial 88107554

IBS.SMART

Reviewed by CopyMark Law Group

Reg. 5922194Status 702Registered
Filing date
Status date
Registration date
Nov 26, 2019
Examiner
HELMERS, SARA A
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with IBS.SMART?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, irritable bowel syndrome; [ Test strips for measuring blood glucose levels; ] Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for medicinal use; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic test strips for blood analysisACTIVEOct 1, 2018

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 3, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Mar 3, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Mar 3, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 25, 2025E815TEAS SECTION 8 & 15 RECEIVED
Nov 26, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 22, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 22, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 22, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 22, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 22, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 5, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 5, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 5, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 5, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 5, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 26, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 23, 2019SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Oct 22, 2019CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 2, 2019DOCKASSIGNED TO EXAMINER
Sep 20, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 19, 2019SUPCSTATEMENT OF USE PROCESSING COMPLETE
Sep 19, 2019EX1GSOU EXTENSION 1 GRANTED
Sep 19, 2019AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 16, 2019IUAFUSE AMENDMENT FILED
Sep 16, 2019EXT1SOU EXTENSION 1 FILED
Sep 16, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 16, 2019EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
May 28, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 14, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 14, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 17, 2019ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Feb 25, 2019ETOFEXTENSION OF TIME TO OPPOSE RECEIVED
Feb 5, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 5, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 16, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 3, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Dec 18, 2018DOCKASSIGNED TO EXAMINER
Dec 17, 2018DOCKASSIGNED TO EXAMINER
Sep 14, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 10, 2018NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance